Worth reading
63In focus
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
191900
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status report for stock acquisition rights with an exercise price adjustment clause
発行・処分する株式数
New shares 191,900 shares / Treasury shares No treasury shares transferred during the relevant month
Existing Shares and Increase
+0.99%Rate of increase
21,320,925 shares21,512,825Shares
0.99% (exercise ratio subject to the exercise limit: number of shares delivered during the relevant month / number of listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
¥280.8, ¥302.4 and ¥315.0 during the relevant month. Details of the exercise price adjustment clause and its floor: Not disclosed
Number of Stock Acquisition Rights
The total number of stock acquisition rights issued can be calculated from the statement that 1,919 exercises represented 2.49% of the total issued, but the number itself is Not disclosed. There were 75,703 unexercised rights at the end of the month preceding the relevant month and 73,784 at the end of the relevant month.
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Transactions.
Most recent equity financing
Development Promotion Stock Acquisition Rights for docirbrutinib (AS-1763) with Exercise Price Adjustment Clause, issued on 17 February 2026
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status report for stock acquisition rights with an exercise price adjustment clause |
| Number of shares to be issued or disposed of | New shares 191,900 shares / Treasury shares No treasury shares transferred during the relevant month |
| Dilution Rate | 0.99% (exercise ratio subject to the exercise limit: number of shares delivered during the relevant month / number of listed shares as of the payment date for the issuance) |
| Total number of issued shares | 21,320,925 shares (as of the end of the month preceding the relevant month, including 11,144 treasury shares) → 21,512,825 shares (calculated by adding the 191,900 new shares delivered during the relevant month to the number of shares outstanding at the end of the preceding month) |
| Exercise price | ¥280.8, ¥302.4 and ¥315.0 during the relevant month. Details of the exercise price adjustment clause and its floor: Not disclosed |
| Number of Stock Acquisition Rights | The total number of stock acquisition rights issued can be calculated from the statement that 1,919 exercises represented 2.49% of the total issued, but the number itself is Not disclosed. There were 75,703 unexercised rights at the end of the month preceding the relevant month and 73,784 at the end of the relevant month. |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Transactions. |
| Most recent equity financing | Development Promotion Stock Acquisition Rights for docirbrutinib (AS-1763) with Exercise Price Adjustment Clause, issued on 17 February 2026 |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This reports the monthly exercise status in October 2026 for the stock acquisition rights issued on 17 February 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.